Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Diabetic Foot Infection (DFI) Market Outlook

Thelansis’s “Diabetic Foot Infection (DFI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Foot Infection (DFI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Foot Infection (DFI) Overview

Diabetic foot infection (DFI) is the most prevalent complication of diabetes mellitus that results in hospitalization and is the leading cause of nontraumatic lower extremity amputation. DFI is an infection in the soft tissues or bones below the malleoli. Diagnosis relies on clinical indicators of inflammation or the presence of pus, with infections categorized as mild, moderate, or severe. Most DFI cases involve multiple microorganisms, with aerobic gram-positive cocci, primarily Staphylococcus species, being the most common pathogens. Osteomyelitis, a severe complication, often necessitates surgical intervention. Clinically detecting foot infection depends on identifying purulent discharge from an ulcer or classic signs of inflammation, such as erythema, pain, tenderness, warmth, or induration. Other suggestive signs include foul odor, necrosis, and delayed wound healing despite optimal care. Managing DFI effectively entails the appropriate antibiotic treatment, surgical drainage, dead tissue debridement and resection, proper wound care, and addressing metabolic issues. FDA-approved therapies for DFI include:

1. Zyvox: Approved for treating DFI caused by Gram-positive bacteria.
2. Zosyn: A bactericidal antibiotic approved for DFI treatment.
3. Integra Omnigraft Dermal Regeneration Matrix: Approved for specific diabetic foot ulcers.

The prognosis for DFI hinges on factors such as vascular blood supply and neuropathy. Renal failure and significant peripheral vascular disease are common risk factors for amputation, and MRSA has emerged as another risk factor for infection progression.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034